ReviewACS bio & med chem Au2026
Epidermal Growth Factor Receptor as a Model Drug Target for Scrutinizing the Status Quo in Drug Discovery and Chemical Biology.
Review in ACS bio & med chem Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Drug discovery scientists and chemical biologists continually seek to improve strategies for compound development. Here, we present insights derived from multiple studies of the epidermal growth factor receptor (EGFR), illustrating how this well-established target can inform practical aspects of drug discovery. Case studies spanning fragment-based drug design, bivalent inhibitor discovery, and the optimization of irreversible covalent inhibitors demonstrate how focused investigation of a single system can serve as a framework for methodological innovation and generation of broadly applicable knowledge. We propose that these collective efforts exemplify an emerging paradigm in medicinal chemistry, wherein "model drug targets" are deliberately leveraged to yield generalizable design principles and uncover new strategies for ligand discovery and chemical probe development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.